Reunion Neuroscience (REUN) Stock Price, News & Analysis

Company Overview

Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company, develops therapeutic solutions for mental health conditions in North America. The company's lead asset includes RE104, a clinical-stage serotonergic psychedelic therapeutic product for antidepressant applications. It is also developing the RE200 series, which comprises molecules that are structurally designed to be similar to classical psychedelics with selective potency at the target serotonin 2A receptor (5HT2A) for potential chronic treatment in various patient populations and indications. The company was formerly known as Field Trip Health Ltd. Reunion Neuroscience Inc. was founded in 2008 and is headquartered in Toronto, Canada.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 339 shs
• Average Volume: 12,447 shs
• Market Capitalization: C$16.64 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

REUN Stock Analysis - Frequently Asked Questions

How do I buy shares of Reunion Neuroscience?

Shares of REUN stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

What other stocks do shareholders of Reunion Neuroscience own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Reunion Neuroscience investors own include Meta Platforms (META) and BioLineRx (BLRX).

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Healthcare
• Current Symbol: TSE:REUN
• CIK: N/A
• Web: www.fieldtriphealth.com
• Phone: 888-519-6016
• Fax: N/A
• Employees: 190
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): C($3.30)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -C$38.10 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -86.35%
• Return on Assets: -26.50%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.52
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: C$4.86 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: C$1.82 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 11,720,000
• Free Float: N/A
• Market Cap: C$16.64 million
• Optionable: Not Optionable
• Beta: 4.20